[go: up one dir, main page]

EP4058033A1 - Polypeptides associés à hmgb1 utiles pour favoriser la régénération tissulaire, compositions les comprenant et leurs utilisations - Google Patents

Polypeptides associés à hmgb1 utiles pour favoriser la régénération tissulaire, compositions les comprenant et leurs utilisations

Info

Publication number
EP4058033A1
EP4058033A1 EP20824631.4A EP20824631A EP4058033A1 EP 4058033 A1 EP4058033 A1 EP 4058033A1 EP 20824631 A EP20824631 A EP 20824631A EP 4058033 A1 EP4058033 A1 EP 4058033A1
Authority
EP
European Patent Office
Prior art keywords
hmgb1
sequence
amino acids
binding
box
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20824631.4A
Other languages
German (de)
English (en)
Inventor
Jagdeep Nanchahal
Alvaro VINALS GUITART
Wyatt YUE
Nicola BURGESS-BROWN
Tzung Yuan Lee
Ana Isabel ESPIRITO SANTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of EP4058033A1 publication Critical patent/EP4058033A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This application incorporate s-by-reference nucleotide sequences which are present in the file named “201112_91203-A-PCT_Sequence_Listing_AWG.txf’, which is 78 kilobytes in size, and which was created on November 12, 2020 in the IBM-PC machine format, having an operating system compatibility with MS-Windows, which is contained in the text file filed November 12, 2020 as part of this application.
  • This disclosure relates to engineered polypeptides related to HMGB1 that promote tissue regeneration without potential for deleterious inflammation and methods of treating an acute tissue injury by administering the engineered polypeptides to subjects in need thereof.
  • HMGB1 High Mobility Group Box 1
  • HMGB1 is a prototypical alarmin [8,9] and under physiological conditions has an essential role in transcription [10,11].
  • G Alert On cell injury it is passively released from the damaged and necrotic cells into the extracellular space and the circulation to act on stem and progenitor cells to transition them to G Alert [7], a state intermediate between G 0 and G 1 [12].
  • G Alert On exposure to the appropriate activating factors, cells in G Alert are able to rapidly enter Gi and effect tissue repair. If not required, stem cells in G Alert revert back to Go after approximately 3 weeks [12], thereby ensuring that they are not exhausted and the niche is not depleted.
  • HMBG1 comprises two L-shaped Box domains, A and B, each containing 3 ⁇ -helices (I - III) connected by flexible regions that are involved in LPS (N-terminus of Box A and adjacent C-terminal linker region) [13] or RAGE (C-terminus of Box B) binding [14].
  • the C- terminus of the protein is intrinsically disordered and contains a high proportion of carboxylic acid residues (Glu/Asp) comprising the acidic tail. This binds to the HMG Boxes to regulate activities, including interactions with TLR-2 [10,15,16] and potentially also RAGE [15] ( Figures 1A-1B).
  • HMGB1 cysteine residues (Cys 22, Cys 44 in Box A and Cys 105 in Box B) is a key determinant of the extracellular activities of HMGB1 and in turn is dependent on the mechanism of release. Three different redox forms have been described in vivo [17].
  • HMGB1 passively released from the nuclei following injury or cell necrosis is the fully-reduced form (FR-HMGB1). It binds to CXCL12 and the heterocomplex signals via the cell surface receptor CXCR4 to transition stem and progenitor cells to G Alert [7] .
  • DS-HMGB1 disulfide HMGB1
  • DS-HMGB1 disulfide HMGB1
  • GS-HMGB1 signaling via the receptor for advanced glycation end products (RAGE) activates platelets and is a key mediator of thrombosis [22,23] .
  • DS-HMGB1 also acts via TLR-4 and TLR-2, leading to release of proinflammatory cytokines, including TNF and IL-6 [24].
  • Intracellular signaling via all three receptors converges to induce NF-k ⁇ activity [25] in a MyD 88 -dependent manner [26,27].
  • Oxidation of all three cysteine residues through the action of extracellular reactive oxygen species results in sulfonyl-HMGB1 (SO 3 ), which is biologically inactive [17,28].
  • the disulfide bridge in Box A of DS-HMGB1 (Cys22-Cys44) is essential for TLR-4 signaling ( Figures 1A-1B), initiating binding to TLR-4 but also has a relatively high dissociation rate.
  • MD-2 then binds to Box B with low affinity but very low dissociation rates, stabilizing the interaction [29]; the Phe-Cys-Ser-Glu (FCSE, 104-107) peptide in Box B is essential for this interaction [30].
  • the capacity of DS-HMGB1 to signal via TLR-4 has been overcome by substituting cysteines at positions 22, 44 and 105 with serine, resulting in an engineered form described as 3S-HMGB1 [17].
  • HMGB1 prothrombotic signaling mediated by RAGE requires the disulfide form of HMGB1, implying that Box A is involved [22].
  • the acidic tail of HMGB1 may negatively regulate RAGE signaling in a manner analogous to TLR- 2 as it binds residues within the RAGE binding peptide [10,15,39] .
  • This invention provides a polypeptide represented by the following formula:
  • A represents consecutive amino acids, the sequence of which (1) includes a sequence identical to the sequence of amino acids 90 - 93 of wild type HMGB1, (2) has at its amino terminal end, between one and six consecutive amino acids, for example, 1, 2, 3, 4, 5, or 6 amino acids, the sequence of which is identical to the sequence of the corresponding one to six amino acids preceding amino acid 90 in wild type HMGB1, and optionally (3) has a methionine at the amino terminus;
  • X represents consecutive amino acids, the sequence of which is identical to the sequence of amino acids 94 - 162 of wild type HMGB1;
  • B represents consecutive amino acids, the sequence of which (1) includes a sequence identical to the sequence of amino acids 163 - 168 of wild type HMGB1 and (2) has at its carboxy terminal end, between one and six consecutive amino acids, for example, 1, 2, 3, 4, 5, or 6 amino acids, the sequence of which is identical to the sequence of the corresponding one to six amino acids following amino acid
  • This invention also provides a composition comprising the polypeptide in accordance with the invention and a carrier, and methods of treating a subject suffering from, or at risk for developing, a condition which would be alleviated by promoting regeneration of a tissue or cells that rely upon CXCR4 + cells for repair which comprise administering to the subject a polypeptide of the invention in an amount effective to promote regeneration of the tissue or cells and a therapeutic or prophylactic dose of a pharmaceutical composition of the invention.
  • Figures 1A-1B show a schematic of the HMGB1 structure and locations of known immunogenic activities.
  • Figure 1A Structure of HMGB1 (PDB 2YRQ, conformer 1, colored in PyMol according to known interactions with LPS, TLR-4 or RAGE. The acidic tail, which is involved in transcriptional modulation and bactericidal activities, is not shown in the structure.
  • Figure IB Schematic representation of binding sites.
  • Original figure coloring shows Box A - blue; Box B - green; Pink: residues involved in glycyrrhizin binding. Red: flexible N- terminal regions adjacent to Box A or Box B; Orange: cysteine residues; White: linker region between HMG Boxes; Bright green and yellow: RAGE binding region (incomplete as it extends into the acidic tail, yellow).
  • Figures 2A-2F show conserved residues in each HMG Box domain are critical for CXCL12 binding and include the N-terminal D-P-X-X tetramer.
  • Figure 2A Peptide array (11x10) of HMGB1 15-mers incubated with 1 ⁇ M CXCL12-His6 and detected with anti-His5- HRP antibody. Intensity of spots corresponds to amount of CXCL12 bound to the peptides; first two and last two spots in the array comprised 10-His positive controls.
  • Figure 2B Intensity quantification of spot intensity in (Figure 2A) (duplicate runs) normalized to 10-his control. Peptides used for alanine scanning experiments have been highlighted.
  • Peptides in the acidic tail were not included, as due to its high negative charge it would non-specifically bind cationic molecules such as CXCL12.
  • Peptides in graphs are represented in SEQ ID NOs: 8- 104, left to right.
  • Figure 2C Peptide array of alanine mutagenesis at single positions within peptides identified in ( Figures 2A-2B). First spot in each row corresponds to the positive control; second spot to the unmodified peptide. Peptides shown are represented in SEQ ID NOs: 105-111.
  • Figure 2D Intensity quantification of the array in ( Figure 2C, SEQ ID NOs: 105-111), normalized to the unmodified peptide.
  • Kd Affinity (Kd) constants from both fits follow the same relationship and are greatly decreased for HMGB1 94-162; analyzed by 1-way Brown-Forsythe ANOVA from the fitted data. Kd values were compared via a post-hoc 2-way ANOVA, averaging both values as no significant differences were found in the paired comparison (column factor). Raw interferograms can be found in Figure 9.
  • Figures 3A-3B show NMR validation of residues involved in CXCL12 binding.
  • Figure 3A Cumulative CSP of helical -only biotinylated Box B (94-162, HMGBlA-c028) or complete Box B (89-174, HMGBlA-c038) after titration with CXCL12 (0.42, 0.84 and 1.42 molar equivalents), calculated over several HSQC spectra including a parallel control with no CXCL12 measured after the last concentration point (CSP drift control). Intensity of the green color in the graph indicates relative CSP.
  • each HMGB1 construct has been overlaid with the residue number; an empty column (no number) represents residues which could not be mapped in the parallel 3D 1 H- 15 N HSQC/NOE/TOCSY experiments.
  • the sequence of the residues corresponding to each HMG Box is shown as follows with original figure coloring: Light blue, residues previously reported in the literature as involved in CXCL12 binding; red, residues weakly involved in the peptide array; purple, residues involved according to both published literature and peptide array. Grey, alanine residues within CXCL12 binding peptides (underlined) that could not be assessed in the peptide arrays. Sequence shown is represented in SEQ ID NO: 5.
  • Figure 3B Cumulative peak height change of (Figure 3A); Heatmap of NMR changes. With original figure coloring, red indicates I/I0 change over 1 SEM of all residues, blue decrease over -1 SEM. Sequence shown is represented in SEQ ID NO: 5.
  • Figures 4A-4C show design of the dBB12L construct.
  • Figure 4A Alignment of Box A + linkers (1-88) (SEQ ID NO: 3) with Box B + linkers (89-174) (SEQ ID NO: 4); values correspond to NMR nomenclature (excluding N-terminal methionine).
  • Vertical lines designate strictly conserved positions, and double dots similar substitutions.
  • Underlined peptide regions binding CXCL12 from the first peptide array.
  • Red residues flagged in the alanine scan as involved in CXCL12 binding which could not be verified by NMR
  • Orange residues flagged in the alanine scan and also showing either CSP or peak volume change by NMR
  • Cyan residues not flagged in our NMR or peptide array experiments but described in the NMR literature as contributing to CXCL12 binding [44]
  • Purple residues flagged peptide array experiments and confirmed by the published or our NMR data
  • Green residues flagged only on NMR experiments, which can either directly bind CXCL12 or be affected by binding to nearby residues
  • Pink residues flagged by both our NMR experiments and the published data.
  • FIG 4B Structure of FR-HMGB1 1-166 (2YRQ), with the residues colored following the same color code as in (Figure 4A). Side chains of all colored residues have been shown. Dashed circles indicate the glycyrrhizin binding region in each HMG Box.
  • Figure 4C Schematic of dBB12L construct design. The initiation codon Met 1 is numbered as Met 0 herein, as it is partially lost in the cleaved peptide. Therefore, HMGB1 Met 1 -Gly 2...Glu 215 becomes Met 0- Gly 1...Glu 214. Domain organization and sequences of FR- HMGB1 (top - SEQ ID NO: 1) and dBB 12L construct (bottom - SEQ ID NO: 2).
  • the dBB 12L construct is designed such that: 1. The acidic tail and part of the RAGE binding domain (175- 214) have been deleted; 2. Residues 1-88 (Box A) have been substituted by residues 89-174, resulting in two HMG Box B domains; and 3. Residues 163-174 C-terminal to Box B replace the native flexible linker (79-88) C-terminal to Box A in native HMGB1. CXCL12 binding peptides are shown as red letters. The repeat Box B units are separated in the diagram by a dashed black line.
  • Figures 5A-5D show dBB12L has similar stability and surface charge conformation to FR-HMGB1 1-214/1-164.
  • Figure 5A Calculated Tm 50 values (in °C) for full-length and 1- 164 FR-HMGB1, and dBB12L. Shading of individual Tm 50 values indicate highest (green) and lowest (red) values within the global dataset for all constructs. N/A: curve not fittable.
  • Figure 5B Native ESI/MS of HMGB1 constructs in either 50 mM or 0.2 M ammonium acetate, pH 6.5.
  • HMGB1 constructs have similar native M/Z profiles, with dBB12L closely resembling a reduced HMGB1 construct with two HMG Boxes apart from each other. Continuous line; compact monomer. Dashed line; extended monomer (HMG Boxes distal to each other). Removal of the acidic tail (FR HMGB1 1-164, blue curves compared to FR- HMGB1, red curves with original figure coloring) and higher ionic strength (Comparison of the spectra for the same construct in either 50 mM or 200 mM ammonium acetate) increases the prevalence of higher M/Z states (partial unfolding).
  • Figure 5C Solvent accessible surface area (SASA) calculations for the average folded HMGB1 monomer, the extended and compact monomer states, and the unfolded monomer from (Figure 5D).
  • Figure 5D Denaturing ESI/MS deconvolution, SDS-PAGE and SEC profiles of HMGB1 constructs after storage at room temperature for 180 days (D0-D180), in 0.2 M ammonium acetate, pH 6.5.
  • Figure 6A-6F show dBB12L has reduced binding to RAGE and does not signal through TLR-2 or TLR-4.
  • DS-HMGB1 binds RAGE more avidly compared to FR- HMGB1. Data normalized with respect to DS-HMGB1 control.
  • DbB-HMGBl did not promote NF-k ⁇ signaling, whereas FR-HMGB1 only induced minor NF-k ⁇ activation in both cell lines, potentially due to partial oxidation during the assay. Values are shown as mean ⁇ SEM fold change compared to control (media alone).
  • Figures 7A-7J show the regenerative effects of optimal doses of dBB-HMGBl and FR- HMGB1 are identical to those of an activating injury.
  • Figure 7A Volcano plot showing differentially expressed genes in muscle stem cells by fold change following injury orHMGBl induced G Alert . Integration demonstrates conserved up- (brown dots in figures with color) and down- (blue dots in figures with color) regulation of core genes in G Alert induced by contralateral lower limb injury or intravenous (iv) HMGB1.
  • Figure 7B Network map of gene ontology terms of differentially expressed cells during G Alert induction in muscle stem cells.
  • Figure 7C Dose response of FR-HMGB1 in a BaCI 2 skeletal muscle injury model, with regeneration quantified by fiber cross-sectional area. The optimal dose was 0.75 mg/kg (28.75 nmol/kg) and was used in subsequent assays.
  • Figure 7D Animals were dosed with FR- HMGB1 (optimal dose) at the varying timepoints after injection of BaCI 2 to assess the interval where treatment with FR-HMGB1 is effective post-injury. Values in ( Figure 7C), ( Figure 7D) shown as mean ⁇ SEM in nested ANOVA with Holm-Sidak correction (values shown for post- hoc tests).
  • Figure 7E Pharmacokinetics of iv HMGB1 in mice, fitted by nonlinear least squares to a two-phase exponential decay curve (circulating HMGB1 after intravenous injection of the optimal dose).
  • Figure 7G Ejection fraction. Dotted line indicates ejection fraction in normal/sham surgery mice.
  • Figure 7H Infarct size compared by 2-way ANOVA for treatment effect across times.
  • Figure 71 Representative mid-ventricular short- axis cine-MRI images at end-diastolic and end-systolic phases of the cardiac cycle 1 and 5 wk after MI.
  • FR-HMGB1 group shows preservation of heart function and maintenance of wall thickness (yellow arrows in figures with color) with visible separation of right and left ventricles (red arrows in figures with color) during systole.
  • wall thickness yellow arrows in figures with color
  • red arrows in figures with color visible separation of right and left ventricles
  • n 10 per group. All MRI scans were performed and assessed by a blinded observer.
  • Figures 8A-8B show results of a peptide array of CXCL12 peptides interacting with HMGB1.
  • Figure 8A Peptide array of full-length CXCL12. “+” positions correspond to positive control 10-His peptides; the rest of the peptides comprise CXCL12 15-mers shifted two (2) residues in succession towards the C-terminus.
  • the membrane was exposed to 1 uM HMGB1(FR or 3S)-His6 (1-214), BoxA-His6 (8-78) and BoxB-His6 (94-162) for 24 hours. Bound protein was detected by anti-His-HRP conjugate chemoluminescence.
  • a peptide of CXCL12 interacting with full length HMGB1 cannot interact with either Box A or Box B alone, confirming the requirement of the N-terminal segment of each Box domain (particularly, D4 in box A/D90 in box B): intensity of the spots pertaining to the common CXCL12 peptide is also markedly decreased upon binding to the Box domains alone when compared to FL- HMGB1. Binding to 3S seems to be of higher intensity than that to FR; this is likely due to protein oxidation during the assay, although this was not quantified due to the low concentration of protein used being unsuitable for ESI/TOF MS. BLI data, however, do suggest a lower off rate of CXCL12 from 3S than from FR-HMGB1.
  • Figure 8B CXCL12 dimer (PDB 2J7Z) with the regions binding HMGB1 highlighted. In original figures with color, Red: shared binding region. Blue: non-shared binding region.
  • FIG. 9 shows interferograms in BLI of CXCL12 binding to immobilized HMGB1 constructs.
  • Biotinylated HMGB1 constructs were immobilized on streptavidin-coated Octet biosensors and dipped in rising concentration of CXCL12.
  • Interferograms are colored according to CXCL12 concentration (key in top right).
  • Each set of three replicates (cycles) for a given sensor is surrounded by a colored overlay according to construct.
  • FR FL-HMGB1 (c011), black: 3S-FL HMGB1 (c022), purple: FR-HMGB1 Box A 8-78 (c027), brown: FR- HMGB1 Box B 94-162 (c028), pink: FR-HMGB1 Box A 1-88 (c037), grey: FR-HMGB1 Box B 90-162 (c038).
  • Figures 10A-10D show NMR validation of residues involved in CXCL12 binding (continuation).
  • Figure 10A Cumulative CSP of HMGB1 3S 1-184 (HMGBlA-c007) upon addition of 1:2 molar equivalents of CXCL12 in one step (1: 1 HMG Box to CXCL12 ratio). Box A and Box B residues have been considered separate molecules for the purposes of median CSP calculation. With the original figure coloring, intensity of the green color in the bar graph indicates higher relative CSP.
  • the sequence of each HMGB1 construct has been overlaid with the residue number; an empty column (no number) represents residues which could not be mapped in the parallel 3D 1H-15N HSQC/NOE/TOCSY experiments.
  • FIG 11 shows Interferograms in BLI of HMGB1 constructs binding to immobilized Fc-RAGE.
  • RAGE-Fc was immobilized in the surface of AHC sensors and dipped in rising concentration of different HMGB1 constructs.
  • Two experiments were run with different concentration ranges: the three columns of graphs in the left, 0 to 22.22 ⁇ M HMGB1 over 9 steps; on the right, 0 to 25 ⁇ M over 7 steps. Both are originally color-coded by concentration (top). Colors indicate the specific construct concentration.
  • Each graph corresponds to a single sensor (replicate).
  • Interferograms surrounded by a red rectangle had data points excluded due to poor quality (e.g. drift).
  • Figure 12 shows histological images of regenerating muscle in response to FR- HMGB1 (red) or dBB12L (green) compared to PBS control (black) in the originally colored figure.
  • Figures 13A-13C shows plasmid vector maps. Vector maps with features and restriction sites. TEV: Tobacco etch virus protease recognition site. 6-His: 10/6-histidine residue affinity epitope. FLAG: FLAG affinity epitope. StrepTag: StreptactinXT affinity epitope. SacB: Levansucrase precursor (negative selection in the presence of sucrose). pLIC: Annealing sites for sequencing primers used in colony screening. All plasmids contain kanamycin resistance (50 ⁇ g/mL).
  • Figure 14 shows mutagenesis of the FR-HMGB1 sequence to generate 3S-HMGB1.
  • engineered means a non-naturally occurring compound that has been created based up changing a naturally occurring compound .
  • An engineered compound e.g. a polypeptide, may include portions of a naturally occurring compound that have been modified or rearranged.
  • Such an engineered polypeptide may also be referred to as an “analogue” or “derivative” of the naturally occurring polypeptide.
  • stem cell means any unspecialized cell that has the potential to develop into many different cell types in the body, including without limitation hemopoietic stem cells.
  • an effective amount means an amount of a compound that is capable of achieving a desired result, for example, alleviating a condition or the symptoms associated therewith, for example, an acute tissue injury as described herein.
  • the specific dose of a compound administered according to this invention will, of course, be determined by the particular acts associated with the condition, for example, the route of administration, the physiological state of the subject, and the severity of the condition being treated.
  • an engineered HMGB1 protein administered to a subject is preferably in the form of a composition comprising a therapeutically effective amount of the engineered HMGB1 protein.
  • pharmaceutically acceptable refers to those compounds, materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material. The choice of any specific pharmaceutically acceptable carriers is well within the knowledge of those skilled in the art. . Accordingly, there is a wide variety of suitable carries available and routinely used in pharmaceutical compositions. [0031] It should be understood that the terms “a” and “an” as used herein refer to “one or more” of the enumerated components.
  • This invention provides a polypeptide represented by the following formula:
  • A represents consecutive amino acids, the sequence of which (1) includes a sequence identical to the sequence of amino acids 90 - 93 of wild type HMGB1, (2) has at its amino terminal end, between one and six consecutive amino acids, the sequence of which is identical to the sequence of the corresponding one to six amino acids preceding amino acid 90 in wild type HMGB1, and optionally (3) has a methionine at the amino terminus;
  • X represents consecutive amino acids, the sequence of which is identical to the sequence of amino acids 94 - 162 of wild type HMGB1;
  • B represents consecutive amino acids, the sequence of which (1) includes a sequence identical to the sequence of amino acids 163 - 168 of wild type HMGB1 and (2) has at its carboxy terminal end, between one and six consecutive amino acids, for example, 1, 2, 3, 4, 5, or 6 amino acids, the sequence of which is identical to the sequence of the corresponding one to six amino acids following amino acid 168 in wild type HMGB1; and wherein
  • the methionine is present at the amino terminus of the polypeptide.
  • A has at its amino terminal end, one amino acid corresponding to amino acid 89 of wild type HMGB1.
  • B has at its carboxy terminal end, six amino acids the sequence of which corresponds to the sequence of amino acids 169-174 of wild type HMGB1.
  • This invention also provides a composition comprising the polypeptide of any one of the provided embodiments and a carrier.
  • the polypeptide is present in a therapeutically or prophylactically effective amount and the carrier is a pharmaceutically acceptable carrier.
  • This invention also provides methods of treating a subject suffering from, or at risk for developing, a condition which would be alleviated by promoting regeneration of a tissue or cells that rely upon CXCR4 + cells for repair which comprise administering to the subject the polypeptide of any one of the provided embodiments in an amount effective to promote regeneration of the tissue or cells, that is, a therapeutically or prophylactically effective dose of the pharmaceutical composition of the invention.
  • the condition is myocardial infarction and the tissue is a cardiac tissue, particularly, myocardium.
  • the polypeptide is administered within 5 hours, preferably within 4 hours, more preferably within 3 hours, even more preferably within 2 hours and most preferably within 1 hour of the myocardial infarction.
  • the condition is a fracture and the tissue is a bone.
  • the condition involves liver damage and the tissue is liver tissue.
  • the condition involves damage to the brain or nervous system and includes stroke, Parkinson’s disease and dementia.
  • the condition involves damage to the lung.
  • the condition involves the gut and includes surgery and inflammatory bowel disease.
  • the condition involves damage to the skin and includes surgical procedures, bums and ulcers.
  • the condition involves the pancreas including type 1 diabetes and the cells are islet cells.
  • the condition is neutropenia, for example, neutropenia following chemotherapy and the tissue is bone marrow.
  • the condition is kidney failure and the tissue is kidney tissue.
  • the first encompassed the initial one and a half ⁇ -helices of the HMG Box, overlapping the glycyrrhizin binding site [41].
  • the second was located at the C- terminal half of the third ⁇ -helix.
  • the first CXCL12 binding peptide (helices I and II) appeared to be the most involved in CXCL12 binding as the intensity of CXCL12 binding to peptides from this segment was much higher.
  • Binding of Box B peptides to CXCL12 appeared to be slightly weaker compared to Box A based on the intensity of the immunoblots.
  • Helical-only constructs had decreased CXCL 12 affinity and binding capacity compared to full HMG Box constructs with intact flanking regions as evidenced by the increased dissociation rates (k 0 ff) of the helical- only constructs without the flanking regions.
  • affinities of CXCL 12 for full-length HMGB1 (FR or 3S) and full HMG Box constructs were comparable to each other and higher than for the helical -only constructs.
  • CXCL 12 binds to a concave pocket on the underside of each HMG Box as shown by peptide array and NMR
  • Non-oxidizable 3S-HMGB1 was used as our full-length construct as the time required for obtaining a full set of 3D spectra at 750 MHz ( 15 N HSQC-TOCSY/NOESY and associated 15 N HSQC spectra) would result in oxidation of FR-HMGB1, altering both the peak resonances and the interaction with CXCL 12.
  • CXCL12 titration ofHMGBl Box B 94-162 ( Figure 3A) resulted in changes inNMR signal, either cumulative chemical shift perturbation (CSP) or peak height changes (I/Io), of several residues at both the C-terminal and N-terminal binding regions identified in the peptide arrays.
  • CSP cumulative chemical shift perturbation
  • I/Io peak height changes
  • CSP changes for residues not identified in the peptide arrays (A147, M131, A169, K172, G173) in the construct with the flanking regions.
  • Other residues that have not been previously identified but were flagged as being potentially important in the peptide arrays did not display either CSP or volume changes upon addition of CXCL12 (C105, E107, Y108). This group of residues was, therefore, reclassified as being not critical for CXCL 12 binding.
  • HMGB1 constructs which preserved these interaction surfaces but altered sequences to attenuate proinflammatory signaling. Based on the fact that each HMG Box can bind to a CXCL12 monomer independently and the requirement of both Box A (oxidized) and Box B for TLR-4 [48] and potentially for the prothrombotic RAGE [14,22] and TLR-2 [22,33] signaling activities, we hypothesized that an HMGB1 construct where Box A is substituted by another Box B (i.e. 1-88 replaced by 89-174) would not signal through TLR-2, TLR-4 or RAGE.
  • This engineered construct dBB12L (Figure 4B) comprised of the following segments of the native HMGB1 protein: flexible N-terminal region (from HMGB1 89-93), first Box B (from HMGB1 94-162), 12-residue linker C-terminal of native Box B (from HMGB1 163-174), and second Box B (from HMGB1 94-162).
  • the linker length of 12 residues in this dBB12L is similar to the 10 amino acids in the linker of native HMGB1. This small increase in linker length was due to our preserving residues 172 and 173 which showed changes in CSP on CXCL12 binding.
  • thermostability of dBB 12L and wild-type HMGB1 using Dynamic Scanning Fluorimetry (DSF), and solvent accessible surface area (SASA) by both native mass spectrometry (native ESI/MS) and size exclusion chromatography (SEC).
  • DSF Dynamic Scanning Fluorimetry
  • SASA solvent accessible surface area
  • dBB12L had similar stability and surface charge profiles as FR-HMGB1 1-164, which also contains two HMG Box domains and no C-terminal acid tail.
  • dBB 12L is not significantly different from an HMGB1 construct with two HMG Boxes alone.
  • dBB12L construct has greatly reduced affinity for RAGE and cannot signal through TLR-2 or TLR-4
  • HMGB1 constructs Three additional HMGB1 constructs were tested, including DS-HMGB1 1-184, which has an intact RAGE binding peptide and oxidized Box A but no acidic tail and therefore has all the requisites for RAGE binding; DS-HMGB1 1-164, which lacks a significant portion of the RAGE binding peptide but retains an oxidized Box A; and DS-Box A alone.
  • DS-HMGB1 1- 184 bound RAGE, but with reduced capacity and affinity compared to full-length DS-HMGB1.
  • DS-HMGB1 1-164 had greatly diminished RAGE binding capacity compared to full-length DS-HMGB1 but still higher than dBB12L, whilst DS Box A 1-88 (full HMG Box construct with flanking regions) was unable to bind RAGE.
  • DS- HMGB1 1 - 164 also had a faster RAGE binding equilibrium with overall lower binding affinity than full length DS-HMGB1, although with higher affinity than dBB12L-HMGBl,
  • the deletion of both the final 10 residues in Box B (175-184) and the disulfide bridge in Box A (by substituting it with Box B) in dBB12L resulted in unstable binding of RAGE.
  • HMGB1 binds TLR-2, TLR-4, and RAGE and signaling from all receptors converges to the NF-k ⁇ pathway [25]. Consequently, it is difficult to attribute downstream proinflammatory cytokine production to a given receptor. Therefore, we first evaluated TLR- specific signaling using NF-k ⁇ reporter cell lines engineered to express either TLR-2 or TLR- 4 and their co-receptors. Disulfide HMGB1 promoted NF-kB signaling via TLR-2 ( Figure 6D) and TLR-4 ( Figure 6E). In contrast, dBB12L failed to signal in either cell type. Next, we confirmed the effects of the various HMGB1 constructs on primary human monocytes.
  • FR-HMGB1 or dBB12L alone did not promote TNF production.
  • FR-HMGB1 or dBB12L reduced TNF expression compared to LPS alone.
  • the dBB12L construct has pro-regenerative activity comparable to that of FR-HMGB1
  • FR-HMGB1 accelerates regeneration of skeletal muscle, bone and blood following injury by promoting the transition of stem and progenitor cells to G Alert [7].
  • stem cells There are no significant stem cells in the mammalian heart and the majority of new cardiomyocytes following injury are derived from existing cardiomyocytes [53]. Therefore, we assessed whether administration of FR-HMGB1 would promote cardiac regeneration.
  • iv injection at the time of myocardial infarction resulted in enhanced survival (83% in mice treated with FR-HMGB1 compared to 52% in PBS controls) (Figure 7F).
  • FR-HMGB1 resulted in approximately 60% reduction in infarct size as assessed by serial MRI scans over 5 weeks (Figure 7H) and 16% improvement in overall left ventricular ejection fraction (Figure 7G).
  • DISCUSSION HMGB1 needs to be modified in order to be used as a tissue repair therapeutic
  • Disulfide HMGB1 can signal through TLR-4 [24,30], TLR-2 [24,34,35] or RAGE [14,63] to induce the expression of proinflammatory cytokines.
  • TLR-4 signaling by DS- HMGB1 results in production of several proinflammatory cytokines, including TNF [28], whilst TLR-2 signaling has been shown to be detrimental in multiple processes, including thrombosis and reperfusion injury [64], and autoimmune disorders [33].
  • DS-HMGB1 signaling via RAGE plays a key role in platelet activation and NET formation by neutrophils to promote thrombus formation [23,64-66].
  • HMGB1 HMGB1
  • Box A and Box B bind CXCL12 independently due to a shared peptide pattern
  • Peptide arrays allowed us to identify the residues [75] involved inHMGBl-CXCL12 interaction.
  • the first peptide region extends from the N-terminal flexible segment into half of Helix II, overlapping with the glycyrrhizin binding site [41], and the second on the C-terminal portion of helix III in each HMG Box.
  • dBB12L The surface area and charge profile of dBB12L also was like that of HMGB1 1-164, with monodisperse profiles in SEC and charge distribution in native ESI/MS. This similarity reflects a similar conformation in solution between dBB12L and a wild-type HMGB1 construct with two HMG Boxes and the linker region (FR-HMGB1 1-164) but without the acidic tail.
  • the engineered dBB12L construct does not signal via TLR-2 or TLR-4 or bind RAGE whilst retaining full pro-regenerative properties
  • HMGB1 Binding of HMGB1 to TLR-4/MD-2 is well-described [29] .
  • Oxidized Box A initiates the binding of DS-HMGB1 by interacting with TLR-4 and Box B stabilizes this interaction by binding MD-2; the FCSE motif within Box B has been shown to be essential for signaling [30] .
  • DS-HMGB1 can signal on its own via TLR-4/MD-2, it can also facilitate signaling via LPS by substituting for LPS-binding protein (LBP) which binds LPS and promotes transfer and recognition to TLR-4/MD-2 [13]. Deletion of Box A in our dBB12L construct effectively precluded signaling via TLR-4.
  • LBP LPS-binding protein
  • HMGB1 The RAGE binding site within HMGB1 (residues 150-183) has been previously described [14]. A similar motif is also present in other RAGE ligands such as S100 proteins, and homologous peptides to these sequences are effective antagonists of HMGB1 -mediated RAGE signaling [37,78].
  • the acidic tail of HMGB1 shares residues with the RAGE binding peptide [15] and has been proposed as a regulator of RAGE interaction, analogous to its role in TLR-2 binding. However, only the disulfide form of HMGB1 has been linked specifically to prothrombotic activities via RAGE [22].
  • dBB12L retains regenerative activity in vivo equivalent to FR-HMGB1.
  • FR-HMGB1 administered intravenously at the time of myocardial infarction resulted in improved survival, reduction in infarct size and improved left ventricular ejection fraction.
  • administration of dBB12L would also promote regeneration of tissues that rely on stem cells for repair such as bone, skeletal muscle and blood, as well as tissues where regeneration is predominantly reliant on mature cell populations such as cardiomyocytes in the heart.
  • dBB12L is likely to be effective if administered up to 5 hours after injury. This is important as the median time for admission to hospital following MI in the USA is 3 hours [83].
  • dBB12L a construct that does not signal via TLR-2 or TLR-4 and fails to effectively bind RAGE was designed.
  • FR-HMGB1 transitions stem cells to G Alert in a manner similar to distant injury despite a short half-life and is effective if administered up to 5 hours after injury.
  • dBB12L promotes tissue regeneration in vivo as effectively as FR-HMGB1. Accordingly, dBB12L can be developed for clinical translation.
  • HMGB1 Reduced High Mobility Group Box 1
  • CXCL12 CXC Ligand 12
  • CXCR4 CXC Receptor 4
  • FR-HMGB1 CXC Ligand 12
  • CXCR4 CXC Receptor 4
  • DS-HMGB1 disulfide form
  • TLR-2 Toll-Like Receptors 2
  • TLR-4 Toll-Like Receptors 2
  • TLR-4 Toll-Like Receptors 2
  • RAGE Receptor for Advanced Glycation End Products
  • Patent 9,623,078 refers to peptides limited to amino acids 1-44 (0-43 for our data) for cardiac regeneration.
  • U.S. Patent Application Publication US 2009/0202500 Al discloses methods for tissue repair but only refers to full-length (1-215) wild-type HMGB1 (0-214 for our data).
  • the dBB12L construct presented herein has no RAGE binding or TFR-4/2 signalling, is 177 amino acids long, and includes amino acid substitutions that have not been previously described. Therefore, the constructs presented herein do not fall within the scope of the prior art.
  • This invention provides polypeptides and methods to harness endogenous regenerative processes to enhance tissue repair.
  • the polypeptides function similarly to fully reduced wild type HMGB1 which promotes tissue regeneration by forming a heterocomplex with two CXCL12 molecules, which in turn signals via CXCR4, likely two adjacent CXCR4 receptors on the cell surface.
  • dBB12L a polypeptide of the invention
  • tissues include tissues where repair is primarily dependent on stem and progenitor cells, such as skeletal muscle and the haemopoietic system, as well tissues where repair is largely dependent on existing mature cells, e.g., cardiomyocytes in the adult mammalian heart.
  • ischemic heart disease affects 153 million people (101), with the loss of >105,000,000 Disability Adjusted Life Years in 2017 (102). Every year 205,000 people in the UK (103) and 805,000 in USA suffer from myocardial infarction (MI), 38% of them experiencing ST-elevation MI (STEMI) (101). Following MI, approximately 30-40% of individuals develop heart failure, affecting 38 million worldwide. Despite US healthcare expenditure for heart failure of >$30 billion in 2012, projected to increase to $70Bn by 2030, 5 -year survival is only -60%, which is worse than most cancers (101). The main target population are patients following MI, especially those at risk of developing heart failure (104).
  • FR-HMGB1 While native FR-HMGB1 promotes functional recovery post MI ( Figures 7F-7I), local conversion to the disulfide form promotes thrombus formation and propagation via RAGE, TFR-2 and TFR-4 (110). Constructs reported by others such as 3S-HMGB1 that retain RAGE binding ( Figure 6B) result in excessive fibrosis and impairment of function following MI (111). FR-HMGB1 also binds RAGE, albeit to a lesser extent than DS-HMGB1 and, therefore, would not be suitable for clinical use.
  • HMGB1 signalling via TLR-2 plays a key role in ischaemia reperfusion injury following myocardial infarction (112) and thrombosis (110),
  • the inventors a have shown the key role of TLR-2 in human atherosclerosis (113).
  • TLR-4 signalling is also crucial in myocardial reperfusion injury (114).
  • the redox conditions in the ischemic and inflamed microcirculation of the damaged heart following myocardial infarction will promote conversion of FR-HMGB1 to the disulfide form (DS-HMGB1), which is a central mediator of thrombosis (110).
  • DS-HMGB1 disulfide form
  • adenoviral transduction and growth factors require intracardiac injection or topical patch application (FSTL1), manipulation of developmental pathways carries oncogenic risk (128) and viral transduction of miRNA199- a in pigs resulted in fatal arrhythmias (127).
  • An alternative strategy for stimulating cardiac regeneration by promoting clearance of immune cells requires repeated injection of VEGF-C (129). Inhibition of MAP4K4 promotes myocardial survival and limits infarct size, but there was no regenerative effect (130). To date, none of these strategies have progressed to clinical trials.
  • This invention provides a unique solution which targets endogenous processes to promote cardiomyocyte survival and regeneration of multiple tissues. It overcomes the many hurdles associated with cell therapies, including anti-fibrotic CAR T cells (131), such as prohibitive expense (132, 133). Since FR-HMGB1 acts via the cell surface receptor CXCR4, it is not expected to have off target effects associated with targeting intracellular processes, e.g. by adenoviral transduction of transcription factors or miRNA.
  • HMGB1 inhibition increased infarct size following ischemia reperfusion injury (134) and whilst local upregulation (135, 136) or intramyocardial injection of FR-HMGB1 has been shown to be effective in both mice (111, 137, 138) and sheep (139), our data indicate iv administration is efficacious and more likely to reach all target cells.
  • the engineered double Box B construct of the invention which avoids deleterious proinflammatory signaling should be safe.
  • Fractures occur following injury. However, one of the commonest skeletal ‘injuries’ is joint replacement or arthroplasty. The inventors propose that dBB12 can be used to promote healing following fracture or arthroplasty, thereby reducing the risk of potential complications such as loosening of components.
  • dBB12L may be used to improve patient outcomes following stroke.
  • Other potential indications include Parkinson’s disease and dementia.
  • dBB12L is contemplated to improve outcomes following lung injury, for example, following Covid-19 or in patients with idiopathic pulmonary fibrosis.
  • liver. 30% of people in the USA are estimated to suffer from non-alcoholic liver disease. 60% of these go on to develop non-alcoholic steatohepatitis and 20% of those develop liver cirrhosis. Treatments are being developed to limit and prevent liver damage from tehse conditions. The inventors propose that dBB 12L to be used in combination with these treatments to promote liver regeneration.
  • Gut. dBB12L may be used to promote healing of the gut, for example, following surgery or patients with inflammatory bowel disease such as ulceractive colitis in combination with treatments to control inflammation.
  • Kidney. dBB12L may be used to promote regeneration of the kideny, thereby potentially avoiding the need for dialysis or kidney transplantation.
  • dBB12L may be used to promote wound healing eg following surgery, bums or patients with ulcers eg diabetic ulders.
  • Pancreas. dBB 12L may be used to improve outcomes in patients with type 1 diabetes mellitus by promoting regeneration of islet cells.
  • Bone marrow. dBB12L may promote regeneration of the haemopoetic system e.g. following chemotherapy, thereby preventing severe potentially life thereatening neutropenia.
  • FR-HMGB1 is effective even if adminsitered up to 2 weeks before injury (142). Since dBB12L is equally efficacious to FR- HMGB1 ( Figure 7J) it is contemplated that this polypeptide may be used prophylactically, for example, by the military or for sports injuries or before elective surgery or chemotherapy.
  • Mach-1 T1R cells Invitrogen, no antibiotic resistance or induction, BL21(DE3)-R3- pRARE2 (in-house BL21 derivative, chloramphenicol resistance 36 ⁇ g/mL , T7-polymerase lac induction [87]) and BL21(DE3)-R3-pRARE2-BirA (in vivo biotinylation derivative of the above, additional spectinomycin resistance 50 ⁇ g/mL) were sourced from chemically competent stocks made in-house.
  • SOC 20 g/L tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 0.1862g/L KC1 were autoclaved and supplemented with 4.132 g/L MgCI 2 and 20 mM glucose.
  • LB Lia Bertani
  • TB Terrific Broth
  • TB supplement 1.6% w/v glycerol, 1% glucose, 25 mM (NH4)2S04, 10 mM MgSO 4 , 10X trace metals, 0.22 ⁇ M sterile filtered.
  • M9 minimal medium 16 g/L Na 2 HPO 4 , 4 g/L K 2 HPO 4 , 1 g/L NaCl, pH 7.2-7.3 and 2.5 g/L FeSO 4 , 0.25 mg/L ZnCI 2 , 0.05 mg/L CuSO 4 , 0.25 g/L EDTA, 1 mM MgSO 4 were autoclaved and supplemented with 4 g/L glucose, 1 g/L U-99% 15 NH4C1 (Cambridge Isotopes), 0.3 mM CaCI 2, 1.5 mg/L D-biotin and 1.5 mg/L Thiamine-HCL from sterile filtered stocks.
  • Plasmids were sourced from the SGC libraries [87]. All plasmids contain a 6xHis tag with a TEV-cleavage site; pNIC-Bio3 and pDsbC-HT-CBio also have C-terminal biotinylation epitopes (which can be removed with a stop codon). Plasmid DNA was linearized by restriction enzyme digestion: BfuAl (3h, 60°C) for pNIC-CTHF or Bsal (2h, 31°C). Cut vector DNA was purified with a PureLink PCR kit and treated with T4 DNA polymerase (NEB M0203) in the presence of 0.25 mM dGTP (pNIC-CTHF) or dCTP as per manufacturer protocols.
  • HMGB1 constructs were sourced from the Mammalian Gene Collection (purified as plasmid from Machl cells grown overnight in LB medium with antibiotics). Constructs were amplified via PCR: a program of 95°C /10' , 25x (95°C/ 30”, 52°C/L, 0.5-1.5 min at 68°C), 68°C/10'was used. Reaction consisted of 5 ⁇ L Herculase II buffer, 1 ⁇ M of each primer, 6 ⁇ g/mL plasmid template, 1 ⁇ M dNTP mixture and 1 unit Herculase II polymerase (Agilent 600679; supplied with buffer and 100 ⁇ M dNTP stocks) in 25 ⁇ L final volume. PCR products were purified before further use (PureLink kit, ThermoFisher K310001).
  • Amplified coding sequences were cloned into the destination vector via ligation independent cloning (LIC).
  • the insert was treated with T4 DNA polymerase in the presence of a cognate nucleotide to that used for the vector (10 ⁇ L reaction volume), and 2 ⁇ L was mixed with 1 ⁇ L of treated vector and annealed for 30‘.
  • 40 ⁇ L ice-cold Mach-1 cells (for storage) or 20 ⁇ L BL21(DE3)-R3-pRARE2/ BL21 (DE3)-R3 -pRARE2-BirA cells (for expression) were added and heat-shocked for 45” at 42°C before chilling in ice.
  • CXCL12 constructs were cloned with an in-frame SUMO protease site N-terminal to the mature protein to allow for periplasmic secretion with an N-terminal fusion protein in the pDsbC-HT-CBio vector (DsbC-SUMO-CXCL12) to avoid addition of N-terminal residues to the protein which could affect its activity [88,89] whilst obtaining folded, oxidized CXCL12 via the DsbC fusion protein system [90]. All mutants were verified by sequencing (SourceBioscience). The sequence for HMGBl-dBB was designed in silico by codon- optimizing a Box B 89-174 sequence according to E.
  • coli BL21-DE3 genome (assembly ASM956vl) placed after the native HMGB1 Box B sequence, and synthetized in vitro by Twist Bioscience (San Francisco, USA) cloned in pNIC-CTHF.
  • Pellets of induced HMGB1 -expressing cells were resuspended at 14 g/L in 1 MNaCl, 5% glycerol, 50 mM HEPES pH 7.5, 10 mM Imidazole (Buffer A) supplemented with 1 : 1000 protease inhibitors (Calbiochem Set III, Merck 539134), 3 ⁇ g/mL Benzonase-MBP, 1 mM MgSO 4 0.5 mg/L lysozyme (Sigma L6876) and 0.5% v/v Triton-XlOO before freezing at - 80°C; from this point onwards all steps took place at 4°C.
  • Contaminants were washed with 15 CV of 0.5 M NaCl, 5% glycerol, 50 mM HEPES pH 7.5 (Buffer B) supplemented with 30 mM imidazole before elution directly into a PD- 10 column (GE Healthcare; equilibrated in Buffer B + 20 mM imidazole) with 2.5 mL of Buffer B + 500 mM imidazole. Proteins were eluted from the column with 3.5 mL of Buffer B + 20 mM imidazole before tag removal with 1:20 OD TEV-GST protease over 16 h.
  • Proteins were further purified by size exclusion chromatography (SEC) (Superdex S75 10/300-0.35 ml./min or 16/600-1.2 mL/min flow rate) in either 10 mM HEPES pH 7.5 + 150 mM NaCl for biophysics work or cell-culture grade PBS for cell and animal work. Recombinant proteins were flash-frozen for storage, adding 1 mM TCEP in the case of reduced HMGB1 proteins.
  • SEC size exclusion chromatography
  • Outer membranes of cells expressing DsbC-SUMO-CXCL12 were lysed by osmotic shock [91]. Pellets were resuspended at 40 g/L in 1 M sucrose, 0.2 M Tris-HCl pH 8.0, 1 mM EDTA, 1 mg/mL lysozyme, 2X cOmplete protease inhibitor set (COEDTAF-RO, Roche), 50 mM Imidazole and 3 ⁇ g/mL benzonase. This was stirred for 45 min at room temperature before adding 4 volumes of ice-cold 18.2 m ⁇ water and mixed for a further 10 min before adding 1 mM MgS04.
  • CaptoS columns CaptoS ImpAct, GE 17-3717-47
  • Proteins were further purified via SEC in the same way as HMGB1 and flash-frozen for storage.
  • Endotoxin was removed in all cases before size-exclusion chromatography via phase separation with Triton Tx-114 [92].
  • a 2% v/v of TX-114 was added to recombinant protein solutions, homogenized for 20' with orbital shaking at 2000 RCF at 4°C, and separated for 5' at 37°C before pelleting the detergent phase at 8000 RCF, 10', 25 °C.
  • the supernatant was mixed with 5% w/v of SM-2 Biobeads (BioRad, 152-8920), cleaned with 2% TX-114 for 2 hours and regenerated with 30 CV of methanol, 30 CV of endotoxin-free 18.2 ihW water and 30 CV of endotoxin-free PBS. This was incubated for 4 hours at room temperature to adsorb remaining Triton and PEG [93] before injection onto a sanitized SEC system (with 0.5 M NaOH contact over 12 h, followed by 0.2 M acetic acid/20% ethanol contact over 6 hours and equilibration in cell-culture grade PBS) to fully remove leftover polymer contaminants whilst performing size exclusion.
  • SM-2 Biobeads BioRad, 152-8920
  • TEV-GST protease (GST-fusion protein), Benzonase-MBP, and Ulp-1 protease were produced from transformants in storage at the SGC collection [87]; all had 200 ⁇ g/mL ampicillin resistance.
  • TEV and Ulp-1 were purified as per the protocols described for HMGB1 with only one IMAC step, whereas Benzonase-MBP was purified from outer membrane lysates obtained as with CXCL12 and isolated with use of amylose resin (NEB, E0821) as per manufacturer protocols. In both cases, the resulting proteins were concentrated to 10 mg/mL in 50 mM HEPES pH 7.5, 0.3 M NaCl, 10% glycerol.
  • GST-TEV protease and Ulp-1 were flash-frozen with liquid nitrogen and supplemented with 0.5 mM TCEP during purification; Benzonase-MBP was supplemented with 50% glycerol and 2 mM MgCI 2 and stored at -20°C.
  • Membranes with FMOC-coupled 15-mer peptides of human HMGB1 (Uniprot P09429) or CXCL12 (Uniprot P48061, excluding secretion signal) were printed by Dr. Sarah Picaud at the SGC upon request following published protocols [40].
  • the membranes were rehydrated at 20-25°C with 95% and 70% ethanol, equilibrated with PBST (PBS IX + 0.05% Tween-20, 3x), and blocked with 10% BSA/PBST for 8 h. 1 ⁇ M of the partner His-tagged protein construct was added (in PBS) and allowed to bind for 24 hours at 4°C.
  • Alanine mutagenesis scans were performed in the same manner, with the printed peptides consisting of those identified during the initial peptide array. Residues whose mutation to alanine resulted in higher intensity changes than those observed for alanine positions in the sequence were considered as significant contributors to CXCL12 binding.
  • Pre-hydrated streptavidin Octet Biosensors (ForteBio 18-5019) were coated with 4 ⁇ M solutions of biotinylated HMGB1 proteins in 10 mM HEPES, pH 7.5, 150 mM NaCl (Base buffer-BB) plus, 0.5 mM TCEP (60 sec baseline, 60 sec binding). Nonspecific binding was minimized by incubation for 3' in BB+ 1% BSA + 0.05% Tween-20 (Kinetics Buffer, KB) prior to kinetics assays.
  • 384-well protein-binding ELISA plates (Santa Cruz Biotechnology, sc-206072) were coated with 50 mE of 40 nM solutions in PBS (+ 0.5 mM TCEP for FR-HMGB1 constructs) of HMGB1 constructs for 24 h, at 4°C, including FL/DS HMGB1 full-length controls and blank, with 4 replicates of each. Nonspecific binding was blocked by incubation with 10% BSA in PBS for 2 h, at 20-25°C.
  • a concentration range of RAGE-Fc chimera protein (BioTechne, 1145-RG; 0-640 nM in 1:4 dilutions) was added in 10% BSA/PBS and allowed to bind for 2 h, at 4°C.
  • Bound FC chimera was detected by incubation with Anti-Human IgG HRP (Agilent Dako P021402-2) diluted 1: 10000 in 1% BSA/PBS for 2 h, at 20-25°C. Between each of these 3 steps, the plate was washed with 100 ⁇ L PBST, 3 times.
  • TMB substrate (ThermoFisherN301) was added to each well; the reaction was allowed to develop in the dark until the FL-DS-HMGB1 control developed a clear concentration-dependent color gradient before stopping the reaction with 25 ⁇ L of 0.5 M H2SO4.
  • OD 450 was measured as a readout (FluoStar OMEGA, BMG Labtech) and plotted as a saturation fit against 2x RAGE-Fc concentration (as the chimera is a RAGE dimer)
  • HEK-Dual cells (Invivogen) expressing human TLR-2 and CD 14 or murine TLR-4, MD-2 and CD14 were maintained in DMEM (Gibco), supplemented with 10 % FBS (Gibco), 1 % L-Glutamine (Gibco), and 1 % penicillin/streptomycin (Gibco), in standard tissue culture conditions (37oC; 5% C02).
  • TLR-4 and TLR-2 HEK-Dual cells were plated in triplicate into wells of a 96 well plate and stimulated with 10 ⁇ g/mL 1 HMGB1 and (X concentration) FSL-1 for TLR-2 and 10 ng/mL LPS for TLR-4. 24 hours after stimulation, NF- kb activity was determined my measuring the induced levels of secreted embryonic alkaline phosphatase (SEAP).
  • SEAP embryonic alkaline phosphatase
  • Human monocytes (StemCell Technologies) were maintained in DMEM (Gibco), supplemented with 10% FBS (Gibco) in standard tissue culture conditions (37°C; 5% C02).
  • DMEM GibCell Technologies
  • FBS Gibco
  • 10 5 human monocytes were plated in triplicate into wells of a 96-well plate and stimulated with 10 ⁇ g/mL HMGB1 and 50 ng/mL LPS or 10 ng/mL LTA. 24 hours after stimulation, TNF levels were determined by Enzyme-linked immunosorbent assays (ELISA) (Abeam).
  • ELISA Enzyme-linked immunosorbent assays
  • mice were treated systemically with an i.v. injection of 30 pg FR-HMGB1 in 50 ⁇ L of PBS vehicle, or PBS only control.
  • Injury cell are from BaCI 2 injured mice as described below.
  • Alert cells are from the uninjured contralateral side of BaCI 2 injured mice.
  • Murine muscle stem cells mMuSCs
  • Muscle cell suspensions were created by mincing thigh muscles and enzymatically digesting with collagenase 800 U/ml (Worthington-Biochem) and dispase 1 U/mL (Gibco). Thereafter, all suspensions were strained through 70 pm and 40 pm filters (Greiner Bio-One) and stained with respective antibodies.
  • RNA-seq analysis using Lexogen 3 ’kit library prep and sequenced using HiSeq400 (Illumina).
  • FASTQ files were assessed using FASTQC followed by the generation of TPM values with kallisto v0.42.4. TPM values were summed to obtain gene-level expression values using tximport and differential expression analysis was undertaken with DeSEQ2.
  • C57BL/6 inbred mouse strain, females of 11-12 weeks of age were purchased from Charles River UK and housed in the local Biological Safety Unit (BSU) at the Kennedy Institute. Acclimatization period was 1-2 weeks. All protocols performed on live animals have been approved by the UK Home Office (PPU 30/3330 and PPU P12F5C2AF) as well as the local animal facility named persons and are registered under the appropriate project and personal licenses under ASPA regulations. All consumables were surgically certified; recombinant proteins were endotoxin-free. Surgeries were done in a clean environment separate from culling facilities. All animals were monitored for 6 hours post-operative ly, and daily for the following 3 days; monitoring was then transferred to the NVS/NACWO.
  • BSU Biological Safety Unit
  • the TA muscles were dissected and further fixed for 24 hours before being embedded in paraffin and sectioned. Sections (5 pm) were stained with hematoxylin and eosin to identify fibers with central nuclei and imaged with an Olympus BX51 using a lOx ocular/ 40x objective lens.
  • the cross-sectional area (CSA) of the fibers from at least 4 images per mice was manually measured using the FIJI distribution of Image J2 software (NIH). Data were grouped per mice.
  • mice were injected with HMGB1 constructs (46 nM/kg, resuspended in PBS) or PBS vehicle control intramuscularly or intravenously at the time of injury or after injury for the optimal time administration of HMGB1 constructs after injury.
  • mice C57BU/6 female mice were subject to surgery between 10-14 weeks old, with body weight between 25-30 g. All mice had either an intravenous injection of FR-HMGB1 (46 nM/kg, resuspended in PBS) or vehicle control just before surgery.
  • Buprenorphine (buprenorphine hydrochloride; Vetergesic) was delivered as a 0.015 mg ml solution via intraperitoneal injection at 20 min before the procedure to provide analgesia. They were anaesthetized with 2.5% isoflurane and externally ventilated via an endotracheal tube.
  • Cardiac cine-MRI was performed post-LAD ligation at 7T using a Varian DDR system. Briefly, mice were anaesthetised with 2% isoflurane in 02, and positioned supine in a custom animal handling system with homeothermic control.
  • HMGB1-C028 (94-162, biotinylated) titration with CXCL12A-c021 at 0, 0.42, 0.82 and 1.42 molar equivalents, Figures 3A-3B.
  • Weissman IL Stem cells: Units of development, units of regeneration, and units in evolution. Cell 2000, 100:157-168.
  • HMGB1 The acidic tail of HMGB1 regulates its secondary structure and conformational flexibility: A circular dichroism and molecular dynamics simulation study. Comput Struct Biotechnol J 2020, 18:1160-1172. Watson M, Stott K, Thomas JO: Mapping Intramolecular Interactions between Domains in HMGB1 using a Tail-truncation Approach. JMol Biol 2007, 374: 1286— 1297. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, Liu J, Antonelli A, Preti A, Raeli L, et al.: Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release.
  • HMGB1 binds to activated platelets via platelet-expressed receptor for advanced glycation end products (RAGE) and is highly expressed in platelet rich coronary artery thrombi. Thromb Haemost 2015, 14:994-1003. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.
  • Non-oxidizable HMGB1 induces cardiac fibroblasts migration via CXCR4 in a CXCL 12-independent manner and worsens tissue remodeling after myocardial infarction. Biochim Biophys Acta - Mol Basis Dis 2017, 1863:2693-2704.
  • HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. J Neuroinflammation 2016, 13:1-12. Hreggvidsdottir HS, Lundberg AM, Aveberger A-C, Klevenvall L, Andersson U, Harris HE: High mobility group box protein 1 (HMGBl)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol Med 2012, 18:224-30. Livoti E: Experimentally validated computational docking to characterize protein- protein interactions.
  • Turchetto J Sequeira AF, Ramond L, Peysson F, Bras JLA, Saez NJ, Duhoo Y, Blemont M, Guerreiro CIPD, Quinton L, et al.: High-throughput expression of animal venom toxins in Escherichia coli to generate a large library of oxidized disulphide- reticulated peptides for drug discovery.
  • Thein M, Sauer G, Paramasivam N, Grin I, Linke D Efficient subfractionation of gram-negative bacteria for proteomics studies. JProteome Res 2010, 9:6135-6147.
  • HMGB1 Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood 128, 2435-2449 (2016). S. Di Maggio, G. Milano, F. De Marchis, A. D'Ambrosio, M. Bertolotti, B. S. Palacios, I. Badi, E. Sommariva, G. Pompilio, M. C. Capogrossi, A. Raucci, Non-oxidizable HMGB1 induces cardiac fibroblasts migration via CXCR4 in a CXCL 12-independent manner and worsens tissue remodeling after myocardial infarction. Biochim Biophys Acta 1863, 2693-2704 (2017). J. Mersmann, F.
  • HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3.
  • Venereau, High mobility group box 1 orchestrates tissue regeneration via CXCR4. J Exp Med 215, 303-318 (2018).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne un polypeptide représenté par la formule suivante : H2N-A-X-B-A-X-B-HOOC dans laquelle A représente des acides aminés consécutifs, dont la séquence (1) comprend une séquence identique à la séquence des acides aminés 90 à 93 de la protéine HMGB1 de type sauvage, (2) possède, au niveau de son extrémité N-terminale, entre un et six acides aminés consécutifs, par exemple, 1, 2, 3, 4, 5 ou 6 acides aminés, dont la séquence est identique à la séquence de un à six acides aminés correspondants précédant l'acide aminé 90 dans la protéine HMGB1 de type sauvage et, éventuellement, (3) possède une méthionine au niveau de l'extrémité N-terminale ; X représente des acides aminés consécutifs, dont la séquence est identique à la séquence des acides aminés 94 à 162 de la protéine HMGB1 de type sauvage ; et B représente des acides aminés consécutifs, dont la séquence (1) comprend une séquence identique à la séquence des acides aminés 163 à 168 de la protéine HMGB1 de type sauvage et (2) possède, au niveau de son extrémité carboxy-terminale, entre un et six acides aminés consécutifs, par exemple, 1, 2, 3, 4, 5 ou 6 acides aminés, dont la séquence est identique à la séquence des un à six acides aminés correspondants suivant l'acide aminé 168 dans la protéine HMGB1 de type sauvage ; et chaque - représente une liaison peptidique entre chacun parmi A et X, X et B, B et A, A et X, et X et B.
EP20824631.4A 2019-11-12 2020-11-12 Polypeptides associés à hmgb1 utiles pour favoriser la régénération tissulaire, compositions les comprenant et leurs utilisations Pending EP4058033A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962934299P 2019-11-12 2019-11-12
PCT/IB2020/060674 WO2021094983A1 (fr) 2019-11-12 2020-11-12 Polypeptides associés à hmgb1 utiles pour favoriser la régénération tissulaire, compositions les comprenant et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4058033A1 true EP4058033A1 (fr) 2022-09-21

Family

ID=73835632

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20824631.4A Pending EP4058033A1 (fr) 2019-11-12 2020-11-12 Polypeptides associés à hmgb1 utiles pour favoriser la régénération tissulaire, compositions les comprenant et leurs utilisations

Country Status (6)

Country Link
EP (1) EP4058033A1 (fr)
JP (1) JP7805925B2 (fr)
KR (1) KR20220137876A (fr)
AU (1) AU2020385059A1 (fr)
CA (1) CA3157785A1 (fr)
WO (1) WO2021094983A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022243932A1 (fr) * 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides associés à hmgb1 utiles pour favoriser la régénération tissulaire, compositions les comprenant et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004763A2 (fr) 2002-07-03 2004-01-15 Fondazione Centro San Raffaele Del Monte Tabor Utilisation de hmgb1 dans le traitement des lesions tissulaires et/ou pour activer la reparation des tissus
US20090069227A9 (en) 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
PT2055308T (pt) 2006-10-30 2017-07-05 Univ Osaka Medicamento para promover a regeneração funcional de tecido danificado
RU2016135937A (ru) 2009-10-28 2018-12-11 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
CA2834255C (fr) 2011-04-26 2021-11-02 Genomix Co., Ltd. Peptide permettant d'induire la regeneration d'un tissu et son utilisation
ES2661500T3 (es) 2012-07-26 2018-04-02 Ospedale San Raffaele S.R.L. Variantes de HMGB1 y sus usos
TR201802122T4 (tr) 2012-10-25 2018-03-21 Genomix Co Ltd HMGB1 fragmanı kullanarak kardiyak infarksiyonun tedavisine yönelik yeni yöntem.

Also Published As

Publication number Publication date
AU2020385059A1 (en) 2022-06-02
CA3157785A1 (fr) 2021-05-20
KR20220137876A (ko) 2022-10-12
WO2021094983A1 (fr) 2021-05-20
JP2023512392A (ja) 2023-03-27
JP7805925B2 (ja) 2026-01-26

Similar Documents

Publication Publication Date Title
JP7030894B2 (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体
JP7517997B2 (ja) プログラニュリンを含む融合タンパク質
KR102559975B1 (ko) 지방산 및 생체분자에 대한 접합에서의 이의 용도
CN104114574B (zh) 结合人补体c5的多肽
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
JP2014519848A (ja) Ｐｃｓｋ９結合ポリペプチドと使用方法
JP6794409B2 (ja) シータデフェンシンによる炎症性プロテアーゼの遮断
EP3558342B1 (fr) Utilisation médicale de l'interféron-lambda pour le traitement de la fibrose
JP2018538356A (ja) 組織修復のための二重特異性治療用タンパク質
EP3481859A1 (fr) Polypeptides solubles fibroblastes du facteur de croissance du récepteur 3 (sfgfr3) et leurs utilisations
TW202500578A (zh) 鬆弛素－２融合蛋白類似物及其使用方法
JP7805925B2 (ja) 組織再生の促進に有用なｈｍｇｂ１に関連するポリペプチド、それを含む組成物、及びその使用
WO2021228052A1 (fr) Inhibiteur du complément macromoléculaire biologique spécifique à une cible, son procédé de préparation et son utilisation
AU2022276188A1 (en) Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
JP2026009888A (ja) アルファ（ｖ）ベータ（６）インテグリン結合タンパク質の計算設計
KR20000053277A (ko) 가용성 폴리펩티드
US20230046828A1 (en) Polypeptides Related to HMGB1 Useful for Promoting Tissue Regeneration, Compositions Comprising Same, and Uses Thereof
US8940702B2 (en) Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity
JP6758022B2 (ja) 血管内皮細胞増殖因子受容体阻害ペプチド
CN116635056A (zh) 长效脱氧核糖核酸酶
JP2022544401A (ja) Ｔｇｆ－ベータトラップ
KR20250166123A (ko) 신경계 복구를 위한 단백질 티로신 포스파타제 웨지 도메인 펩티드 이량체
CN117384269A (zh) 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用
JP2019205355A (ja) 分子改変体アディポネクチン及び分子改変体アディポネクチンを含む医薬組成物
KR20090102317A (ko) ＲＢ1ＣＣ1 단백질 또는 Ｒｂ1ｃｃ1 유전자를 함유하는항암제

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079283

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240110